Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Upgrades Mesoblast to Overweight, Raises Price Target to $11

Author: Benzinga Newsdesk | July 23, 2024 01:56pm
Piper Sandler analyst Edward Tenthoff upgrades Mesoblast (NASDAQ:MESO) from Neutral to Overweight and raises the price target from $4 to $11.

Posted In: MESO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist